title: New Gram-Positive Agents: the Next Generation of Oxazolidinones and Lipoglycopeptides.
abstract: The growing problem of antimicrobial resistance among bacterial pathogens, including methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant enterococci (VRE), has reached a critical state. Tedizolid phosphate, dalbavancin, and oritavancin have recently been approved by the U.S. Food and Drug Administration (FDA) for the treatment of acute bacterial skin and skin structure infections (ABSSSI) and represent the next generation of oxazolidinones and lipoglycopeptides. All three agents exhibit in vitro activity and clinical efficacy against MRSA. Tedizolid phosphate and oritavancin demonstrate in vitro activity against VRE. These new Gram-positive agents are reviewed here.
authors.affiliation: Department of Pharmacy, Methodist Dallas Medical Center, Dallas, Texas, USA.
authors.forename: Matthew P
authors.initials: MP
authors.lastname: Crotty
authors.affiliation: Department of Pharmacy, Barnes-Jewish Hospital, St. Louis, Missouri, USA.
authors.forename: Tamara
authors.initials: T
authors.lastname: Krekel
authors.affiliation: Department of Pathology & Immunology, Washington University in St. Louis School of Medicine, St. Louis, Missouri, USA.
authors.forename: C A
authors.identifier: 0000-0002-1137-840X
authors.initials: CA
authors.lastname: Burnham
authors.affiliation: Department of Pharmacy, Barnes-Jewish Hospital, St. Louis, Missouri, USA Department of Pharmacy Practice, St. Louis College of Pharmacy, St. Louis, Missouri, USA djr0519@bjc.org.
authors.forename: David J
authors.initials: DJ
authors.lastname: Ritchie
mesh_terms: D000890:Anti-Infective Agents / Q000494:pharmacology*; D017277:Drug Approval; D006020:Glycopeptides / Q000494:pharmacology*; D016908:Gram-Positive Bacterial Infections / Q000453:epidemiology* / Q000382:microbiology; D006801:Humans; D000077427:Lipoglycopeptides; D055624:Methicillin-Resistant Staphylococcus aureus / Q000187:drug effects*; D010755:Organophosphates / Q000494:pharmacology*; D010080:Oxazoles / Q000494:pharmacology*; D017334:Teicoplanin / Q000031:analogs & derivatives* / Q000494:pharmacology; D014481:United States; D065507:Vancomycin-Resistant Enterococci / Q000187:drug effects*; D014640:Vancomycin / Q000031:analogs & derivatives
chemical_list: D000890:Anti-Infective Agents; D006020:Glycopeptides; D000077427:Lipoglycopeptides; D010755:Organophosphates; D010080:Oxazoles; D017334:Teicoplanin; C469289:dalbavancin; C515040:tedizolid phosphate; C100708:oritavancin; D014640:Vancomycin